Pancreatic cancer kills fast. Fewer than 13% of patients see five years. Surgery, chemo, immunotherapy—standard care buys time, rarely more. But new follow-up data from a small phase 1 trial hints at something different. Nearly all patients whose immune systems fired up against their tumors after a tailored mRNA vaccine remain alive six years later.
Donna Gustafson remembers the odds stacked against her. Diagnosed with operable pancreatic ductal adenocarcinoma, she joined the trial at Memorial Sloan Kettering Cancer Center. First came surgery to cut out the tumor. Then, tumor snippets went to BioNTech and Genentech labs. There, they sequenced mutations, picked up to 20 neoantigens—unique tumor fingerprints—and baked them into autogene cevumeran, an mRNA vaccine delivered in lipid nanoparticles. Gustafson got eight priming doses over nine weeks, plus a checkpoint inhibitor called atezolizumab upfront and standard mFOLFIRINOX chemo after. Nine doses total. Her T cells woke up. They targeted those neoantigens.
She is cancer-free today. Six years out.
Dr. Vinod Balachandran leads the work. He directs MSK’s Olayan Center for Cancer Vaccines. Back in 2021, initial results showed eight of 16 patients mounted strong T cell responses. Median recurrence-free survival? Not reached for responders at 1.5 years, versus 13.4 months for non-responders. A Nature paper last year doubled down: at 3.2-year median follow-up, responders held a median recurrence-free survival still unreached. Non-responders? 13.4 months. Hazard ratio of 0.14. T cell clones persisted, some projected to last 7.7 years on average, up to a century in theory. Cytotoxic. Tissue-resident memory-like. Effector function intact.
Now the six-year update, presented April 20 at the American Association for Cancer Research annual meeting in San Diego. Of those eight responders, seven live on—87.5% survival at 4-6 years post-surgery. Non-responders? Just two of eight, median survival 3.4 years. Two responders recurred; their tumors showed fewer vaccine-induced T cells, pruned of targeted clones. Gustafson and six others? No recurrence. “These early results show this new immunotherapy approach has the potential to be groundbreaking for one of the deadliest cancers,” Balachandran said in an MSK release.
Skeptics point to the sample. Sixteen patients. Phase 1 focuses on safety, dosing—not efficacy. All had early-stage, resected tumors; favorable prognosis already. Chemo and immunotherapy helped. Responders might just be outliers. Balachandran agrees more proof waits. But the signal endures. T cells absent pre-vaccine, now long-lived sentinels against microscopic disease.
BioNTech and Genentech moved fast. Phase 2 launched last year: randomized, 260 patients across sites. Autogene cevumeran plus atezolizumab and mFOLFIRINOX versus chemo alone post-resection. Endpoints? Recurrence-free survival, overall survival. Recruiting now, per MSK’s trial page. If positive, phase 3 follows. Scalability looms large. Personalized means sequencing tumors quick—weeks, not months. Manufacturing per patient. Costly. Complex.
And alternatives brew. Off-the-shelf shots sidestep personalization. One targets KRAS, mutated in 90% of cases. Early trial: 85% immune response. MSK data from August 2025 in another release: two-thirds mounted T cells at 20 months; responders saw 29-month median overall survival, 15-month recurrence-free. Broader reach, if it works.
But KRAS isn’t alone. Pancreatic tumors cloak themselves. Fibrotic stroma. Suppressive cells. Low mutations, few neoantigens. Experts once thought no immune response possible. This trial flips that. mRNA, post-surgery, primes fresh immunity before relapse. Responders’ T cells multiply, persist through chemo—86% of clones at substantial levels three years out.
NBC News broke the story April 19, drawing from Balachandran’s team. “It was unclear whether the immune response would last and lead to the patients living longer,” he told them then. Now it seems it might. NBC’s coverage spotlighted Gustafson. Slashdot echoed it April 19, linking back. CNN followed April 20: “It’s exciting. The implication is that you can make a very strong immune response against the toughest of cancers, and it can last for this long.” CNN article.
Challenges ahead. Not every patient responds—50% here. Biomarkers? Tumor mutation burden? HLA type? Phase 2 tests combos, maybe boosters. Manufacturing scale. Reimbursement for bespoke drugs. Equity—who gets access?
Still. Six years. Seven of eight alive. In pancreatic cancer, that’s defiance. Larger trials will tell if it’s real. For now, responders like Gustafson live proof: mRNA can train the body to hunt its own killer.
Balachandran’s group pushes on. KRAS vaccines. Broader neoantigen pools. Memory T cells that outlast patients. Pancreatic cancer won’t yield easy. But these shots strike at its core.
WebProNews is an iEntry Publication